🔥 VEXAS + the 🫁 🔥 🔑 Points ~ 🫁 involvement common 👉cough + dyspnea 🌬PFTS often normal 🩻 CXR useful but HRCT superior 🩻ground glass opacity commonest finding 💊 good response GC 🔥ignite session🔥 #ACR22 Abst# 1569 @RheumNow

Abs 0345 finds association between cumulated HCQ and development of cardiac abnormalities. We need further data to determine clinical association. #ACR22 @RheumNow https://t.co/WmixbFIlfd https://t.co/2Ejwkeu1Az

• Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosu…

In the absence of other high risk factor for thrombosis, Thrombocytopenia (ITP) could be an independent and long-lasting clinical phenotype for aPLs carriers. Abs 0672 #ACR22 @RheumNow https://t.co/LmlruGqkEJ https://t.co/MaIHS0QWN0

• Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphosph…

Sometimes we guess how RA pts will be, before they come in. machine learning to predict RA dx activity: RISE registry (n=39,155) inputs: prev CDAI, demo, smoking/obesity, SES v good performance Past performance does predict future outcomes, sometimes! ABST0905 #ACR22 @RheumNow https://t.co/Ir1YG1cqlD

Kajiyama et al. JAKi counteract cellular toxicity of HCQ in vitro. Could they prevent HCQ-retinopathy? @rheumnow #ACR22 Abstr#0653 https://t.co/c0a4OYCzw5 https://t.co/X7pFM7j1R4

• JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro - AC…

RheumNow’s expanded coverage of the #ACR22 meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty

Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720 https://t.co/JPtPCqah9R https://t.co/bonRzWFbVw

• Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Pa…

Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6

• Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Tre…

What neonatal factors could affect development into axSpA? Turns out antibiotic exposure (6.2x more likely). Mode of delivery, early diet (milk vs. formula), maternal smoking (!!) did not show association. @RheumNow #ACR22 Abs#0868 #ACRBest https://t.co/roCAj5YsCt

In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA

• Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in…

Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x

• Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythemat…

🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946 SLE, birth control, & pregnancy planning 🔥30% of women used no birth control despite only 17% voicing interest in pregnancy 🔥More 1/2 of women interested in pregnancy were not medically ready #ACR22 @RheumNow

Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm

• Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflamma…

Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2

• Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarker…

Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr

• Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specific…